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1. Introduction {#sec0001}
===============

Since the emergence of the 2019 novel coronavirus (2019-nCoV) infection in Wuhan, China, in December 2019 [@bib0001], it has rapidly spread across China and many other countries [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008]. So far, 2019-nCoV has affected more than 43 000 patients in 28 countries/regions and has became a major global health concern (<https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=6f80d1b9_4>). On 11 February 2020, the World Health Organization (WHO) announced a new name for the epidemic disease caused by 2019-nCoV: coronavirus disease (COVID-19). Regarding the virus itself, the International Committee on Taxonomy of Viruses has renamed the previously provisionally named 2019-nCoV as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [@bib0003].

Although early studies reported a link between a single local fish and wild animal market and most cases of infection, indicating possible animal-to-human transmission, studies have increasingly demonstrated human-to-human transmission of SARS-CoV-2 through droplets or direct contact [@bib0002],[@bib0008], [@bib0009], [@bib0010]. Moreover, according to one study, presumed hospital-related transmission of SARS-CoV-2 was suspected in 41% of patients [@bib0008]. Based on the evidence of a rapidly increasing incidence of infections [@bib0011] and the possibility of transmission by asymptomatic carriers [@bib0012], SARS-CoV-2 can be transmitted effectively among humans and exhibits high potential for a pandemic [@bib0005],[@bib0010],[@bib0013]. In addition to the high transmission efficiency of SARS-CoV-2, the advancement and convenience of global travel could further enhance its worldwide spread [@bib0012]. On 30 January 2020, the WHO declared the COVID-19 outbreak as the sixth public health emergency of international concern, following H1N1 (2009), polio (2014), Ebola in West Africa (2014), Zika (2016) and Ebola in the Democratic Republic of Congo (2019). Therefore, health workers, governments and the public need to co-operate globally to prevent its spread [@bib0014].

2. SARS-CoV-2 and COVID-19 {#sec0002}
==========================

In addition to seasonal influenza, reported pathogens of pneumonia include adenovirus, coronavirus 229E/NL63/OC43, human bocavirus, human metapneumovirus, parainfluenza virus 1/2/3, rhinovirus and respiratory syncytial virus A/B [@bib0015], [@bib0016], [@bib0017], [@bib0018]. Moreover, these viruses can cause co-infection in the setting of community-acquired bacterial pneumonia [@bib0016], [@bib0017], [@bib0018]. Using molecular methods, knowledge about the role of these viruses in the setting of pneumonia has achieved significant advancements [@bib0019], [@bib0020], [@bib0021]. SARS-CoV-2 was found to be a positive-sense, single-stranded RNA virus belonging to the genus Betacoronavirus [@bib0022], [@bib0023], [@bib0024]. Phylogenetic analysis revealed that SARS-CoV-2 is closely related (88--89% similarity) to two bat-derived SARS-like coronaviruses, namely bat-SL-CoVZC45 (GenBank accession no. **[MG772933.1]{.ul}**) and bat-SL-CoVZXC21 (GenBank accession no. **[MG772934.1]{.ul}**), but it is more distant from SARS-CoV (\~79% similarity) and Middle East respiratory syndrome coronavirus (MERS-CoV) (\~50% similarity) [@bib0023],[@bib0025],[@bib0026]. Chen et al*.* applied an RNA-based metagenomic next-generation sequencing approach to identify a human coronavirus from two pneumonia cases during the Wuhan outbreak in 2019 [@bib0027]. Its entire genome was 29 881 bp in length [@bib0027]. Phylogenetic analysis indicates that SARS-CoV-2 is similar to the coronavirus circulating in *Rhinolophus* (horseshoe bats), with 98.7% nucleotide similarity to the partial RNA-dependent RNA polymerase (*RdRp*) gene of the bat coronavirus strain BtCoV/4991 (GenBank **[KP876546]{.ul}**, 370 bp sequence of *RdRp*) and 87.9% nucleotide similarity to bat coronavirus strain bat-SL-CoVZC45 and bat-SL-CoVZXC21. Evolutionary analysis based on ORF1a/1b, S and N genes suggests that SARS-CoV-2 is more likely a novel coronavirus that was independently introduced from animals to humans [@bib0027]. Based on the findings of genomic investigations and the presence of some bats and live animals in the seafood market in Wuhan, SARS-CoV-2 may have originated from bats or bat droppings associated with contaminated materials in the market or surrounding region [@bib0025],[@bib0028].

3. Epidemiology {#sec0003}
===============

Based on observations of data from the early outbreak in mainland China from 10--24 January 2020, the trend of an increasing incidence largely follows exponential growth, and the mean basic reproduction number (*R* ~0~) was estimated to range from 2.24 \[95% confidence interval (CI) 1.96--2.55\] to 3.58 (95% CI 2.89--4.39), associated with two- to eight-fold increases in the reporting rate [@bib0011]. Another estimation based on data from 31 December 2019 to 28 January 2020 suggested similar findings, with the *R* ~0~ for COVID-19 being 2.68 \[95% credible interval (CrI) 2.47--2.86\] and the epidemic doubling time being 6.4 days (95% CrI 5.8--7.1 days) [@bib0029]. The current estimate of the mean incubation period for COVID-19 is 6.4 days, ranging from 2.1 days to 11.1 days (2.5th to 97.5th percentile) [@bib0030], with potential asymptomatic transmission. Although the situation is evolving and further updated data are required to confirm these estimations, there is great potential for a large outbreak of COVID-19 soon.

As of 11 February 2020, data from the WHO showed that there were a total of 43 103 cases of COVID-19 ([Fig. 1](#fig0001){ref-type="fig"}, [Fig. 2](#fig0002){ref-type="fig"} ) (<https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=6f80d1b9_4>). There has been a steady rise in the daily total number of COVID-19 cases globally, both within and outside China ([Fig. 1](#fig0001){ref-type="fig"}). Regarding new cases of COVID-19, a declining trend was found globally ([Fig. 2](#fig0002){ref-type="fig"}A), in China but not outside China ([Fig. 2](#fig0002){ref-type="fig"}B), mainly in international conveyance (Japan) on 11 February 2020. Twenty-eight countries/regions have reported confirmed cases, including mainland China, Japan, Singapore, Hong Kong Special Administrative Region (SAR), Thailand, South Korea, Taiwan, Australia, Malaysia, Germany, Vietnam, the USA, Macao SAR, the United Arab Emirates, Canada, France, the Philippines, the UK, Italy, India, Russia, Finland, Sweden, Sri Lanka, Cambodia, Nepal, Spain and Belgium. China has had the largest number of patients with COVID-19 (*n* = 42 690), followed by Singapore (*n* = 45) ([Fig. 3](#fig0003){ref-type="fig"} A). Asia has had most of the reported cases, followed by Europe, North America and Australia, but no cases have been reported in Africa. Within China, Hubei has endured the largest number of infected patients (*n* = 31 728), followed by Guangdong (*n* = 1177), Zhejiang (*n* = 1117) and Henan (*n* = 1105) ([Fig. 3](#fig0003){ref-type="fig"}B). A total of 1017 mortalities have been reported globally, with only 2 mortalities occurring outside of mainland China, one each in Hong Kong SAR and the Philippines. According to the Taiwan Centers for Disease Control (<https://www.cdc.gov.tw/En>), as of 12 February 2020 there were 45 167 cases of COVID-19 reported from 28 countries/region and 1115 (2.5%) of patients had died. Among the 45 167 cases, most were found in mainland China (*n* = 44 653) and the reported mortality was 2.5% (*n* = 1113).Fig. 1Daily accumulative cases of laboratory-confirmed cases of 2019 coronavirus disease (COVID-19) as of 11 February 2020: (A) daily numbers of global cases; and (B) daily numbers of cases from China \[including Hong Kong Special Administrative Region (SAR) and Macau SAR\] and outside of China.Fig 1Fig. 2New daily cases of laboratory-confirmed 2019 coronavirus disease (COVID-19) as of 11 February 2020: (A) daily numbers of new cases globally; and (B) daily numbers of new cases from China \[including Hong Kong Special Administrative Region (SAR) and Macau SAR\] and outside of China.Fig 2Fig. 3Distribution of laboratory-confirmed cases of 2019 coronavirus disease (COVID-19) (A) globally by country and (B) in China by province/region as of 11 February 2020.Fig 3

4. Clinical manifestations {#sec0004}
==========================

As of 10 February 2020, only three relatively large-scale case studies have thoroughly demonstrated the clinical features of patients with pneumonia caused by SARS-CoV-2 (SARS-CoV-2 pneumonia) in Wuhan [@bib0004],[@bib0005],[@bib0008]. Herein, we summarise the clinical manifestations of the 278 pooled patients with SARS-CoV-2 pneumonia, which is also referred to as novel coronavirus pneumonia or Wuhan pneumonia ([Table 1](#tbl0001){ref-type="table"} ). All of the patients were adults older than 18 years of age, and males comprised 61.9% of the patients (*n* = 172). A recent study in Beijing reported that 2 of the 13 patients with SARS-CoV-2 pneumonia were children aged between 2--15 years [@bib0009]. As of 10 February 2020, more than 20 paediatric cases have been reported in China, 10 of whom were identified in Zhejiang Province and were in the age range of 112 days to 17 years [@bib0031]. Among adult patients, cardiovascular disease and hypertension were the most common underlying diseases, followed by diabetes mellitus. Fever was the most common symptom (92.8%; *n* = 258), followed by cough (69.8%; *n* = 194), dyspnoea (34.5%; *n* = 96), myalgia (27.7%; *n* = 77), headache (7.2%; *n* = 20) and diarrhoea (6.1%; *n* = 17). Rhinorrhoea was noted in only 4.0% [@bib0004], a sore throat in 5.1% [@bib0004] and pharyngalgia in 17.4% [@bib0008] of patients with relevant clinical information. Most patients had a normal white blood cell count, but 56.8% (*n* = 158) of patients had leukopenia. In one study, patients requiring intensive care were significantly older and more likely to have underlying diseases [@bib0008], but another study showed different findings [@bib0005]. According to two studies, patients admitted to the intensive care unit (ICU) were more likely to have dyspnoea than non-ICU patients [@bib0005],[@bib0008]. Among the 13 patients with SARS-CoV-2 pneumonia reported in Beijing, 12 (92.3%) had fever with a mean duration of 1.6 days before hospitalisation [@bib0009]. Other symptoms included cough (46.3%), upper airway congestion (61.5%), myalgia (23.1%) and headache (23.1%) [@bib0009]. Although some of the epidemiological characteristics were identified, considerable uncertainties are still present and additional studies are needed with detailed information from confirmed cases [@bib0032].Table 1Demographic data, underlying medical conditions, clinical manifestations and laboratory findings from three studies of 278 patients with SARS-CoV-2 pneumonia in Wuhan, China [@bib0004],[@bib0005],[@bib0008][a](#tb1fn1){ref-type="table-fn"}.Table 1Huang et al. [@bib0005] (*n* = 41)Chen et al. [@bib0004] (*n* = 99)Wang et al. [@bib0008] (*n* = 138)Study siteWuhan local health authorityWuhan Jinyintan HospitalZhongnan Hospital of Wuhan UniversityAge (years)49 (41--58)55.5 (13.1)56 (42--68)≥65 years6 (14.6)NANASex Male30 (73.2)67 (67.7)75 (54.3) Female11 (26.8)32 (32.3)63 (45.7)Presumed hospital-related infectionNANA57 (41.3)Healthcare workerNANA40 (29.0)Any co-morbidity13 (31.7)50 (51.5)64 (46.4)Co-morbidities Cardiovascular disease6 (14.6)40 (40.4)20 (14.5) Hypertension6 (14.6)NA43 (31.2) Diabetes8 (19.5)12 (12.1)14 (10.1) Respiratory disease1 (2.4)1 (1.0)4 (2.9) Malignancy1 (2.4)1 (1.0)10 (7.2) Chronic kidney diseaseNANA4 (2.9) Chronic liver disease1 (2.4)NA4 (2.9)Symptoms and signs Fever40 (97.6)82 (82.8)136 (98.6) Cough31 (75.6)81 (81.8)82 (59.4) Dyspnoea22/40 (55.0)31 (31.3)43 (31.2) Sputum production11/38 (28.9)37 (26.8) Myalgia18 (43.9)11 (11.1)48 (34.8) Headache3/38 (7.9)8 (8.1)9 (6.5) Diarrhoea1/38 (2.6)2 (2.0)14 (10.1) RhinorrhoeaNA4 (4.0)NA Sore throat or pharyngalgiaNA5 (5.1)24 (17.4)Duration of onset to dyspnoea8 (5--13)NA5 (1--10)Duration of onset to hospital admission7 (4--8)NA7 (4--8)Duration of onset to ARDS9 (8--14)NA8 (6--12)Laboratory findings White blood cell count (× 10^9^/L)6.2 (4.1--10.5)7.5 (3.6)4.5 (3.3--6.2) Neutrophil count (× 10^9^/L)5.0 (3.3--8.9)5.0 (3.3--8.1)3.0 (2.0--4.9) Lymphocyte count (× 10^9^/L)0.8 (0.6--1.1)0.9 (0.5)0.8 (0.6--1.1) Platelet count (× 10^9^/L)164.5 (131.5--263.0)213.5 (79.1)163 (123--191) aPTT (s) (range)27.0 (24.2--34.1)27.3 (10.2)31.4 (29.4--33.5) PT (s) (range)11.1 (10.1--12.4)11.3 (1.9)13.0 (12.3--13.7) Creatine kinase (U/L)132.5 (62.0--219.0)850 (51--184)92 (56--130) ALT (U/L)32.0 (21.0--50.0)39 (22--53)24 (16--40) AST (U/L)34 (26--48)34 (26--48)31 (24--51) Total bilirubin (mmol/L)11.7 (9.5--13.9)15.1 (17.3)9.8 (8.4--11.1) Creatinine (μmol/L)74.2 (57.5--85.7)75.6 (25.0)72 (60--87) Lactate dehydrogenase (U/L)286 (242--408)336 (260--447)261 (182--403)[^1][^2]

5. Imaging {#sec0005}
==========

Radiological findings of SARS-CoV-2 pneumonia are variable. More than 75% of patients presented with bilateral lung involvement [@bib0004],[@bib0005],[@bib0008],[@bib0032], and multilobe involvement was also common (71%) [@bib0033]. Ground-glass opacity (GGO) was the most common finding from chest computed tomography (CT) [@bib0008],[@bib0034], and in a series of 21 patients, 86% had GGO on chest CT and 29% showed consolidation [@bib0033]. Approximately one-third of patients showed a peripheral distribution of GGO. In contrast, no discrete nodules, cavitation, pleural effusion or lymphadenopathy were observed on the chest CT images [@bib0033],[@bib0034]. Another study including 51 cases showed similar findings [@bib0035]: most CT images showed pure GGO (77%), followed by GGO with reticular and/or interlobular septal thickening (75%), GGO with consolidation (59%) and pure consolidation (55%). Of the 51 cases, 86% showed bilateral lung involvement, and the above findings were peripherally distributed in 86% of cases [@bib0035].

6. Potential treatment options {#sec0006}
==============================

According to recent reports [@bib0004],[@bib0005],[@bib0008], \>85% of patients received antiviral agents, including oseltamivir (75 mg every 12 h orally), ganciclovir (0.25 g every 12 h intravenously) and lopinavir/ritonavir tablets (400/100 mg twice daily orally). Empirical antibiotics were prescribed for 90% of patients in three reports [@bib0004],[@bib0005],[@bib0008], and according to one study 15 patients (15%) received antifungal agents [@bib0004]. Five cases (5.1%) of bacterial (*n* = 1) or *Candida* (*n* = 4) co-infections were reported among 99 patients in one study [@bib0004], and 4 cases (9.8%) of secondary bacterial infections were reported in another study of 41 patients [@bib0005] ([Table 2](#tbl0002){ref-type="table"} ). Although intravenous immunoglobulin and systemic steroids have been used in several reports [@bib0004],[@bib0005],[@bib0008], their efficacy and associated adverse effects remain unclear.Table 2Treatment and outcomes of 278 patients with SARS-CoV-2 pneumonia in Wuhan, China [@bib0004],[@bib0005],[@bib0008].Table 2Huang et al. [@bib0005] (*n* = 41)Chen et al. [@bib0004] (*n* = 99)Wang et al. [@bib0008] (*n* = 138)Treatment Antiviral treatment38 (92.7)75 (75.8)124 (89.9) Antibiotic treatment41 (100)70 (70.7)138 (100) Antifungal treatmentNA15 (15.2)NA Corticosteroid treatment9 (22.0)19 (19.2)62 (44.9) CRRT3 (7.3)9 (9.1)2 (1.4) IVIg therapyNA27 (27.3)NA Invasive mechanical ventilation2 (4.9)4 (4.0)17 (12.3) ECMO2 (4.9)3 (3.0)4 (2.9)Complications ARDS12 (29.3)17 (17.2)27 (19.6) Acute kidney injury3 (7.3)3 (3.0)5 (3.6) Acute cardiac injury5 (12.2)NA10 (7.2) Co- or secondary infection4 (9.8)5 (5.1)NA Shock3 (7.3)4 (4.0)12 (8.7) ICU unit admission13 (31.7)23 (23.2)36 (26.1) Mortality6 (14.6)11 (11.1)6 (4.3)[^3][^4]

So far, there has been no effective treatment of COVID-19. Several potential drug candidates, including lopinavir/ritonavir (Kaletra^Ⓡ^), nucleoside analogues, neuraminidase inhibitors, remdesivir, umifenovir (Arbidol^Ⓡ^), DNA synthesis inhibitors (such as tenofovir disoproxil and lamivudine), chloroquine and Chinese traditional medicines (such as ShuFeng JieDu or Lianhua Qingwen capsules), have been proposed [@bib0036],[@bib0037]. In addition, an angiotensin-converting enzyme 2 (ACE2)-based peptide, 3CLpro inhibitor (3CLpro-1) and a novel vinylsulfone protease inhibitor, theoretically, appear to show potential for antiviral activity against SARS-CoV-2 [@bib0038]. Chloroquine has been well described with in vitro effects on inhibition of uncoating and/or alteration of post-translational modifications of newly synthesised proteins, especially inhibition of glycosylation in many viruses, including human immunodeficiency virus (HIV) [@bib0039]. Preliminary in vivo clinical studies suggest that chloroquine alone or in combination with antiretroviral agents might play an interesting role in treating HIV infection [@bib0039]. A recent study by Wang et al. revealed that remdesivir and chloroquine were highly effective in the control of 2019-nCoV in vitro [@bib0037]. In addition to the one case of SARS-CoV-2 pneumonia with a promising clinical response to remdesivir [@bib0007] and two clinical trials in China, further case-controlled clinical studies of remdesivir therapy are warranted to verify its therapeutic efficacy.

7. Outcomes {#sec0007}
===========

In the three pooled studies of 278 patients [@bib0004],[@bib0005],[@bib0008], 72 patients (25.9%) with SARS-CoV-2 pneumonia required ICU admission, 56 (20.1%) developed acute respiratory distress syndrome, and 23 (8.3%) and 9 (3.2%) required invasive mechanical ventilation and extracorporeal membrane oxygenation for refractory hypoxemia, respectively ([Table 2](#tbl0002){ref-type="table"}). Shock was observed in 19 patients (6.8%), acute kidney injury in 11 patients (4.0%) and continuous renal replacement therapy was required in 14 patients (5.0%). Acute cardiac injury was reported in 5 patients (12.2%) in one study [@bib0005] and 10 patients (7.2%) in another study [@bib0008]. Although two earlier studies demonstrated that SARS-CoV-2 pneumonia was associated with high mortality rates of 11.1% (*n* = 11) [@bib0004] and 14.6% (*n* = 6) [@bib0005], one recent study showed a mortality rate of 4.3% (*n* = 6) [@bib0008] ([Table 2](#tbl0002){ref-type="table"}). Among 13 patients with SARS-CoV-2 pneumonia outside of Wuhan, as of 4 February 2020 all of the patients recovered but 12 were still being quarantined in hospital in Beijing [@bib0009]. It might be suggested that the real-world mortality rate may be lower than that reported in a few published clinical series, when clinical data from more systematic testing would be available, and as the ratio between fatality cases and total reported cases of COVID-19 on 12 February 2020 was currently 0.025 (mortality rate 2.5%). However, most deaths developed in male and elderly patients [@bib0004],[@bib0040]. The median number of days from the appearance of the first symptom to death was 14 days, and it was significantly shorter among patients aged ≥70 years (11.5 days) compared with those aged \<70 years (20 days) (*P* = 0.033) [@bib0040].

8. Infection control and prevention {#sec0008}
===================================

To decrease the damage associated with COVID-19, public health and infection control measures are urgently required to limit the global spread of the virus [@bib0035]. Experience from the early phase of SARS-CoV-2 pneumonia strongly highlighted that travel history, rather than chest radiography, is of paramount importance for early detection and isolation of SARS-CoV-2 pneumonia cases [@bib0041]. It is essential to limit human-to-human transmission in order to reduce secondary infections among close contacts and healthcare workers and to prevent transmission amplification events and further international spread from China. Based on previous experience of management of MERS and SARS infections, the WHO recommend infection control interventions to reduce the general risk of transmission of acute respiratory infections, including avoiding close contact with people suffering from acute respiratory infections, frequent hand-washing especially after direct contact with ill people or their environment, and avoiding unprotected contact with farm or wild animals. Moreover, people with symptoms of acute respiratory infection should practice cough etiquette, which is to maintain distance, cover coughs and sneezes with disposable tissues or clothing, and wash hands, and within healthcare facilities enhanced standard infection prevention and control practices are recommended in hospitals, especially in emergency departments [@bib0042]. The US Centers for Disease Control and Prevention (CDC) has established interim clinical guidance for the COVID-19 outbreak to implement aggressive measures to slow the transmission of SARS-CoV-2 in the USA [@bib0043]. These measures include identification of cases and their contacts in the USA as well as appropriate assessment and care of travellers arriving from mainland China to the USA [@bib0043]. All efforts are being made to slow the spread of the illness in order to provide time to better prepare healthcare systems and the general public, to better characterise COVID-19 to guide public-health recommendations, and to develop timely diagnostics, therapeutics and vaccines [@bib0043]. Finally, although the improvement of internet communication largely enhances the availability and dissemination of knowledge, the internet also has the potential for the development and spread of misinformation or fake news. Governments should be responsible for providing accurate knowledge and clarifying misinformation to help the public face this novel infection.

9. Unresolved issues {#sec0009}
====================

Despite the whole world\'s efforts to understand COVID-19, many issues remain unclear. First, one report has demonstrated the presence of SARS-CoV-2 in patient stools [@bib0007]. However, whether SARS-CoV-2 can be transmitted through the faecal--oral route remains unclear. Second, previous studies showed that SARS-CoV and other coronaviruses could survive on environmental surfaces and inanimate objects [@bib0044],[@bib0045]; however, the presence of SARS-CoV-2 in the environment has not been reported. Previous studies have shown that coronaviruses could be efficiently inactivated using surface disinfectants with 62--71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite within 1 min, but other biocidal agents such as 0.05--0.2% benzalkonium chloride or 0.02% chlorhexidine digluconate were less effective [@bib0045]. However, current investigation of the efficacy of commonly used disinfection agents against SARS-CoV-2 is lacking. Third, although travel restriction was exerted in many countries, whether this intervention was effective is unclear. Fourth, although one case responded well to remdesivir [@bib0007] and one in vitro study [@bib0037] showed that remdesivir and chloroquine were promising for the treatment of COVID-19, further clinical trials on the effectiveness of remdesivir and chloroquine for treating SARS-CoV-2 pneumonia should be conducted. Fifth, although several studies have reported the clinical features of COVID-19 [@bib0004],[@bib0005],[@bib0008],[@bib0009], all of the patients had pneumonia and were treated in Wuhan and Beijing. Most recently, an article has described 1099 patients with acute respiratory disease (ARD) caused by SARS-CoV-2 treated at 552 hospitals across 31 provinces/provincial municipalities in China [@bib0046]. The article reported that only 43.8% of patients had a initial presentation of fever, and severe pneumonia occurred in 15.7% of cases. The study indicated the median incubation period to be 3.0 days (range, 0--24.0 days) and the fatality rate to be only 1.36% [@bib0046]. However, further evaluation of the content of the above report is warranted to clarify the epidemiological and clinical characteristics of asymptomatic carriers and of ARD and pneumonia caused by SARS-CoV-2. Finally, although 32.4% (*n* = 90) of the reported 278 cases with SARS-CoV-2 pneumonia received systemic steroid therapy [@bib0004],[@bib0005],[@bib0008], a study on the temporal features of the SARS-CoV-2‐induced inflammatory response in relation to the timing of therapeutic interventions is lacking. Previous experiences of systemic steroids in the treatment of coronavirus-related infections, such as SARS and MERS, showed disappointing results. In the interim, clinical use of glucocorticoids to control SARS-CoV-2 pneumonia with the intention of regulating cytokine production and the inflammatory response and avoiding lung injury should be avoided [@bib0047],[@bib0048].

10. Conclusions {#sec0010}
===============

The outbreak of COVID-19 has become a clinical threat to the general population and healthcare workers worldwide. However, knowledge about this novel virus remains limited. The effective option of antiviral therapy and vaccination are currently under evaluation and development. What we can do now is aggressively implement infection control measures to prevent the spread of SARS-CoV-2 via human-to-human transmission. Public health authorities should keep monitoring the situation, as the more we learn about this novel virus and its associated outbreaks, the better we can respond.
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[^1]: NA, not available; ARDS, acute respiratory distress syndrome; aPTT, activated partial thromboplastin time; PT, prothrombin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

[^2]: Data are *n* (%), *n*/*N* (%), mean (standard deviation) or median (interquartile range).

[^3]: CRRT, continuous renal replacement therapy; IVIg, intravenous immunoglobulin; ECMO, extracorporeal membrane oxygenation; ARDS, acute respiratory distress syndrome; NA, not available; ICU, intensive care unit.

[^4]: ^a^Data are number (%) of confirmed patients.
